Insomnia / circadian

In peri/postmenopausal women, estrogen loss destabilizes thermoregulation, producing nocturnal hot flashes and sweats that fragment sleep; replacing estradiol reduces vasomotor arousals and thereby restores sleep continuity. Estrogen also has modest direct effects on sleep architecture and REM, but for this condition the dominant lever is symptom-driven awakenings.

Strong for the VMS-associated phenotype, though modest in magnitude. In a 3-arm double-blind RCT (n=339), 0.5 mg/day oral estradiol improved subjective sleep quality (PSQI change -2.2 vs -1.2 placebo, p=0.04) but did NOT significantly reduce insomnia severity on the dedicated ISI endpoint (p=0.09) (PMID 25325454). The 4-year KEEPS RCT (n=727) found oral and transdermal estradiol plus micronized progesterone reduced insomnia versus placebo only intermittently, reaching significance at select timepoints (PMID 27779568). Effects are real but modest, and the benefit is tied to hot-flash relief rather than primary insomnia.

Anecdotal community signal (reports, not evidence): menopausal women and prescribers commonly describe restoring estradiol (often transdermal patches or gel) as the change that ends years of 3 a.m. awakenings once VMS are controlled; some titrate the evening dose or add progesterone specifically for sleep. This aligns with the trial data for the VMS phenotype but is not proof for insomnia without hot flashes.

Context, not a protocol: trials used oral 17-beta estradiol 0.5 mg/day or transdermal estradiol 50 mcg/day, paired with a progestogen in women with a uterus. Clinical menopausal-hormone-therapy dosing is individualized.

Unopposed estrogen is contraindicated in women with an intact uterus (endometrial cancer risk) and must be combined with a progestogen. Standard MHT contraindications apply: history of estrogen-sensitive cancer, VTE/thromboembolic disease, active liver disease, and unexplained vaginal bleeding. Benefit for sleep is largely limited to women with vasomotor symptoms; it is not indicated for primary insomnia.

• Effects of estradiol and venlafaxine on insomnia symptoms and sleep quality in women with hot flashes. ↗
• Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study. ↗

DSIP was originally isolated from rabbit cerebral venous blood during induced sleep and is proposed to promote slow-wave (delta) sleep and modulate neurotransmitter balance (serotonin, glutamate, dopamine, melatonin). The precise receptor and downstream pathway remain poorly defined, which is a major gap for a candidate hypnotic.

Preclinical, with only weak correlational human data. Sleep-promoting and latency-shortening effects have been shown in engineered DSIP-fusion peptides in chemically-induced (PCPA) and pentobarbital mouse models (PMIDs 39444618, 28462721). The one human dataset here is correlational: CSF DSIP-like immunoreactivity tracked with slow-wave sleep in 15 drug-free schizophrenic men-an association, not a treatment trial (PMID 1475566). No modern controlled clinical efficacy data exist; the grade is preclinical to reflect this honestly.

Anecdotal community signal (individual reports, not evidence): DSIP circulates in the research-peptide and biohacking market as a subcutaneous pre-sleep injection, with users describing deeper or more restorative sleep and vivid dreams while others report no effect. Product identity, purity, and dosing are unverified.

Context, not a protocol: community use centers on roughly 100-500 mcg subcutaneously before bed; there is no validated clinical dose, formulation, or safety-tested regimen for DSIP in insomnia.

Sourced almost entirely from unregulated research-chemical suppliers with attendant purity, sterility, and contaminant risks. Peptide stability and true content are frequently uncertain, and there is no controlled safety data for chronic use. Treat any human use as experimental.

• Secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models. ↗
• Expression and Purification of Delta Sleep-Inducing Peptide Fused with Protein Transduction Domain and Human Serum Albumin in Pichia pastoris. ↗
• Delta sleep-inducing-peptide-like immunoreactivity (DSIP-LI) and delta sleep in schizophrenic volunteers. ↗

Pineal peptide preparations (Epithalon/Epithalamin/Pineamin) are hypothesized to stimulate pineal melatonin synthesis and thereby normalize circadian signaling in melatonin-deficient aging. The rationale is circadian restoration via increased nocturnal melatonin rather than direct sedation.

Preclinical-grade despite involving humans, because the data are small, methodologically weak, and measure a surrogate, not sleep. The main human report found Pineamin (100 mg course) increased nocturnal urinary 6-sulfatoxymelatonin ~1.9-fold in 55 elderly patients with diminished pineal function, echoing older Epithalamin work (PMID 28849889). This is a low-quality single-group melatonin-metabolite study from one Russian research group, with no controlled insomnia or objective sleep endpoints. Grade preclinical is honest.

Anecdotal community signal (subjective and confounded reports, not data): N-Acetyl Epithalon Amidate is used in the longevity/biohacking community as short subcutaneous or intranasal courses, with users citing hoped-for anti-aging, telomerase, and sleep/circadian benefits. Nothing approaching controlled sleep data exists.

Context, not a protocol: community regimens typically run short cycles of roughly 5-10 mg/day subcutaneously for 10-20 days, sometimes repeated seasonally; the cited clinical work used a 100 mg Pineamin course. No validated insomnia dosing exists.

Supplied through unregulated research-peptide channels with purity and sterility concerns; the human evidence base is essentially one Russian research group and a surrogate endpoint. If circadian melatonin support is the goal, exogenous melatonin has far better data. Treat as experimental.

• [Pineamin increased pineal melatonin synthesis in elderly people]. ↗

PACAP is co-expressed with melanopsin in the intrinsically photosensitive retinal ganglion cells that relay light to the suprachiasmatic nucleus (SCN) via the retinohypothalamic tract, helping encode light intensity and duration for circadian entrainment. It is a candidate lever for circadian-misalignment insomnia because it shapes how the master clock responds to light.

Preclinical only. PACAP-deficient mice show light-parameter-dependent deficits in photic entrainment (intensity-dependent phase delays, duration-dependent phase advances), blunted masking that is rescued by PACAP-38 infusion, and abnormally early activity onset (PMID 20174586). This defines a genuine role in circadian photoreception but is entirely animal/mechanistic; there are no human insomnia or circadian-therapy data.

Anecdotal community signal: essentially none for insomnia. PACAP appears in the research-peptide space mostly around neuroprotection, migraine (where PACAP antagonism is the drug-development direction), and metabolism, not sleep. No meaningful community sleep-use pattern exists.

Not applicable-no human dosing, route, or protocol for insomnia or circadian indications has been established. Preclinical work used PACAP-38 infusion in animals.

PACAP is a potent vasoactive/migraine-triggering peptide (systemic PACAP-38 provokes headache and flushing in humans), so any notion of administering it for circadian effect carries real off-target risk. The migraine field is pursuing PACAP blockade, underscoring that its systemic pharmacology is not benign.

• PACAP-deficient mice exhibit light parameter-dependent abnormalities on nonvisual photoreception and early activity onset. ↗

Fezolinetant is a neurokinin-3 (NK3) receptor antagonist that blocks KNDy-neuron signaling on the hypothalamic thermoregulatory center, reducing hot flashes and night sweats without hormones. As with estradiol, the sleep benefit in this condition is largely downstream of fewer nocturnal vasomotor arousals rather than a direct sedative action.

Strong for menopausal VMS-related sleep disturbance, though the sleep endpoint is secondary and modest. Pooled analysis of the double-blind, placebo-controlled SKYLIGHT 1 and 2 RCTs showed fezolinetant 45 mg significantly reduced VMS frequency/severity and improved PROMIS Sleep Disturbance scores versus placebo (mean difference -1.60, 95% CI -2.71 to -0.49, p=0.005 at week 12), including in women unsuitable for hormone therapy (PMID 40044127). This is regulatory-grade RCT evidence for VMS; note the drug is approved for vasomotor symptoms, not for insomnia per se.

Anecdotal community signal (consistent with trial data but reports, not proof): menopausal patients-especially those who cannot or will not take estrogen (e.g., breast cancer history)-describe reclaiming uninterrupted sleep once night sweats stop, while some note limited benefit and cost/access barriers.

Context, not a protocol: the approved dose is 45 mg orally once daily; the 30 mg dose was also studied. Not a hypnotic and not dosed as one.

Hepatotoxicity is the key flag-baseline and periodic liver function testing is required, and it is contraindicated in hepatic impairment and with strong CYP1A2 inhibitors. It treats vasomotor symptoms, not primary insomnia; expect no sleep benefit in patients without hot flashes.

• Fezolinetant effect on vasomotor symptoms due to menopause in women unsuitable for hormone therapy. ↗

Oral micronized progesterone is metabolized to allopregnanolone and related neurosteroids that are positive allosteric modulators of the GABA-A receptor, the same target family as benzodiazepines and Z-drugs, producing sedation and promoting sleep onset and slow-wave sleep. This GABAergic route is distinct from estradiol's VMS-mediated effect, which is why it is dosed at night.

Emerging. A randomized comparative trial in 100 menopausal women with insomnia (all also on estradiol) found micronized progesterone 100 mg improved PSQI from ~10 to ~6, comparable to dydrogesterone, but the study had no placebo arm to isolate the progesterone effect and the between-group difference was not significant (p=0.08) (PMID 28609128). In the KEEPS RCT, progesterone was a component of the MHT regimens that intermittently reduced insomnia, again not isolated from estrogen (PMID 27779568). Mechanism is strong; placebo-controlled monotherapy data are lacking.

Anecdotal community signal (reports, not proof): menopausal patients and integrative clinicians frequently move the full progesterone dose to bedtime for its sedating, sleep-onset effect, and many describe it as the more sleep-active half of their hormone therapy. Some without a uterus request it off-label purely as a sleep aid. Widely reported but not established by controlled trials.

Context, not a protocol: oral micronized progesterone 100-200 mg taken at bedtime is the range seen in menopausal practice and the cited trials; the sedating effect is a rationale for evening dosing.

Sedation can be pronounced and additive with other CNS depressants, alcohol, and Z-drugs. The oral micronized form is the sleep-relevant one; synthetic progestins and non-oral routes do not reliably produce the same neurosteroid sedation. Standard progestogen considerations (breast history, mood effects) apply; benefit is best supported in the menopausal context, not as a general hypnotic.

• The effect of different progestogens on sleep in postmenopausal women: a randomized trial. ↗
• Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study. ↗

Acts on the pineal axis to stimulate evening melatonin secretion and normalize circadian cortisol.

Aged rhesus monkey study is the primary support; animal-only, no human sleep trials.

No verifiable community threads located.

No human sleep/circadian dosing established.

Extrapolation from a primate hormone study; research-use-only.

• Regulatory effect of Epithalon on production of melatonin and cortisol in old monkeys ↗